Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Condition:   Non-Myeloid Malignancy Interventions:   Drug: YPEG-rhG-CSF;   Drug: rhG-CSF/PEG-rhG-CSF Sponsors:   Xiamen Amoytop Biotech Co., Ltd.;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting

Source: ClinicalTrials.gov - July 10, 2020 Category: Research Source Type: clinical trials